Novavax (NVAX) Q2 Earnings and Revenues Top Estimates

Group 1 - Novavax reported quarterly earnings of $0.62 per share, exceeding the Zacks Consensus Estimate of a loss of $0.07 per share, representing an earnings surprise of +985.71% [1] - The company posted revenues of $239.24 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 102.74%, compared to year-ago revenues of $415.48 million [2] - Novavax has consistently surpassed consensus EPS estimates over the last four quarters [2] Group 2 - The stock has underperformed the market, losing about 16.3% since the beginning of the year, while the S&P 500 has gained 7.1% [3] - The company's earnings outlook will be crucial for future stock performance, with current consensus EPS estimates at -$0.22 for the coming quarter and $2.54 for the current fiscal year [4][7] - The Zacks Industry Rank indicates that the Medical - Biomedical and Genetics sector is currently in the bottom 42% of over 250 Zacks industries, which may impact stock performance [8]